Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - bicalutamidum inn - filmuhúðuð tafla - 150 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - bicalutamidum inn - filmuhúðuð tafla - 50 mg

Islandia - Islandia - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf.* - gemcitabinum hýdróklóríð - innrennslisstofn, lausn - 1000 mg

Uni Eropa - Islandia - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Uni Eropa - Islandia - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastic lyfjum - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Uni Eropa - Islandia - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Uni Eropa - Islandia - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - Æxlishemjandi lyf - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.